HPV-FASTER: broadening the scope for prevention of HPV-related cancer

被引：153

作者：

Xavier Bosch, F. ^{[1
]}

Robles, Claudia ^{[1
]}

Diaz, Mireia ^{[1
]}

Arbyn, Marc ^{[2
]}

Baussano, Iacopo ^{[3
]}

Clavel, Christine ^{[4
,5
]}

Ronco, Guglielmo ^{[6
]}

Dillner, Joakim ^{[7
,8
]}

Lehtinen, Matti ^{[9
]}

Petry, Karl-Ulrich ^{[10
]}

Poljak, Mario ^{[11
]}

Kjaer, Susanne K. ^{[12
,13
]}

Meijer, Chris J. L. M. ^{[14
]}

Garland, Suzanne M. ^{[15
,16
,17
]}

Salmeron, Jorge ^{[18
]}

Castellsague, Xavier ^{[1
,19
]}

Bruni, Laia ^{[1
]}

de Sanjose, Silvia ^{[1
]}

Cuzick, Jack ^{[20
]}

机构：

[1] IDIBELL, Catalan Inst Oncol, Inst Catala Oncol, Canc Epidemiol Res Programme,Unit Infect & Canc U, Ave Gran Via 199-203, Barcelona 08908, Spain

[2] Sci Inst Publ Hlth, Unit Canc Epidemiol, Brussels, Belgium

[3] Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France

[4] Univ Reims, Ctr Hosp Univ CHU Reims, Reims, France

[5] INSERM, UMR S 903, Reims, France

[6] Ctr Canc Prevent CPO, Canc Epidemiol Unit, Turin, Italy

[7] Karolinska Inst, Dept Lab Med, Stockholm, Sweden

[8] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden

[9] Univ Tampere, Sch Hlth Sci, FIN-33101 Tampere, Finland

[10] Klinikum Wolfsburg, Dept Obstet & Gynaecol, Wolfsburg, Germany

[11] Univ Ljubljana, Fac Med, Inst Microbiol & Immunol, Ljubljana, Slovenia

[12] Danish Canc Soc, Res Ctr, Virus Lifestyle & Genes, Copenhagen, Denmark

[13] Univ Copenhagen, Rigshosp, Dept Gynaecol, DK-2100 Copenhagen, Denmark

[14] Vrije Univ Amsterdam, Med Ctr, Dept Pathol, Amsterdam, Netherlands

[15] Royal Hosp Women, Dept Microbiol & Infect Dis, Parkville, Vic, Australia

[16] Univ Melbourne, Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia

[17] Univ Melbourne, Dept Obstet & Gynaecol, Parkville, Vic 3052, Australia

[18] Ctr Invest Salud Poblac, Inst Mexicano Seguro Social, Unidad Invest Epidemiol & Serv Salud, Inst Nacl Salud Publ, Cuernavaca, Morelos, Mexico

[19] CIBER Epidemiol & Salud Publ CIBERESP, Barcelona, Spain

[20] Queen Mary Univ London, Wolfson Inst Prevent Med, Ctr Canc Prevent, London, England

来源：

NATURE REVIEWS CLINICAL ONCOLOGY | 2016年 / 13卷 / 02期

关键词：

CERVICAL INTRAEPITHELIAL NEOPLASIA; HUMAN-PAPILLOMAVIRUS VACCINATION; COST-EFFECTIVENESS; ADULT WOMEN; FOLLOW-UP; AS04-ADJUVANTED VACCINE; CLINICAL-TRIALS; DOUBLE-BLIND; YOUNG-WOMEN; GRADE;

D O I：

10.1038/nrclinonc.2015.146

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Human papillomavirus (HPV)-related screening technologies and HPV vaccination offer enormous potential for cancer prevention, notably prevention of cervical cancer. The effectiveness of these approaches is, however, suboptimal owing to limited implementation of screening programmes and restricted indications for HPV vaccination. Trials of HPV vaccination in women aged up to 55 years have shown almost 90% protection from cervical precancer caused by HPV16/18 among HPV16/18-DNA-negative women. We propose extending routine vaccination programmes to women of up to 30 years of age (and to the 45-50-year age groups in some settings), paired with at least one HPV-screening test at age 30 years or older. Expanding the indications for HPV vaccination and much greater use of HPV testing in screening programmes has the potential to accelerate the decline in cervical cancer incidence. Such a combined protocol would represent an attractive approach for many health-care systems, in particular, countries in Central and Eastern Europe, Latin America, Asia, and some more-developed parts of Africa. The role of vaccination in women aged > 30 years and the optimal number of HPV-screening tests required in vaccinated women remain important research issues. Cost-effectiveness models will help determine the optimal combination of HPV vaccination and screening in public health programmes, and to estimate the effects of such approaches in different populations.

引用

页码：119 / 132

页数：14